search
Back to results

Treatment of Allergic Rhinitis and Chronic Polypous Rhinosinusitis With Olfactory Mucosa-derived Mesenchymal Stem Cells

Primary Purpose

Allergic Rhinitis, Rhinosinusitis Chronic

Status
Not yet recruiting
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Olfactory mucosa-derived mesenchymal stem cells
Standard treatment of type Allergic Rhinitis according to the clinical protocols
Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols
Sponsored by
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Allergic Rhinitis

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical diagnosis of allergic rhinitis or chronic polyposis rhinosinusitis
  • The patient can read, understand, follow the examination procedures and complete, if necessary, the required documentation
  • Written informed consent

Exclusion Criteria:

  • The presence of any malignant tumor within the last 5 years
  • Acute or chronic diseases in the stage of decompensation
  • Chronic infectious diseases: HIV, viral hepatitis B, C, tuberculosis
  • Patients who are pregnant, breastfeeding, or fertile patients who are not using adequate contraceptive methods
  • Chronic and protracted mental disorders, all diseases with the presence of the syndrome of dependence on alcohol, drugs and psychoactive substances, any other condition that makes the patient unable to understand the nature, extent and possible consequences of the study or, in the opinion of the researcher, prevents the patient from observing and performing protocol
  • Patients are unable or unwilling to give written informed consent and / or follow research procedures
  • Any other medical condition that, in the opinion of the investigator, may be associated with an increased risk to the patient or may affect the outcome or evaluation of the study

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    Experimental

    Active Comparator

    Active Comparator

    Arm Label

    Patients with allergic rhinitis receiving standard treatment and mesenchymal stem cells

    Patients with chronic rhinosinusitis receiving standard treatment and mesenchymal stem cells

    Patients with allergic rhinitis receiving standard treatment

    Patients with chronic polypous rhinosinusitis receiving standard treatment

    Arm Description

    Group 1: Patients with allergic rhinitis receiving standard treatment and olfactory mucosa-derived mesenchymal stem cells

    Group 2: Patients with chronic polypous rhinosinusitis receiving standard treatment and olfactory mucosa-derived mesenchymal stem cells

    Group 3: Patients with allergic rhinitis receiving standard treatment

    Group 4: Patients with chronic polypous rhinosinusitis receiving standard treatment

    Outcomes

    Primary Outcome Measures

    The relapse-free period
    The duration of the relapse-free period
    The relapse-free period
    The duration of the relapse-free period
    The need for surgical intervention
    The need for surgical intervention
    The need for the use of basic drug therapy
    The need for the use of basic drug therapy
    The need for the use of basic drug therapy
    The need for the use of basic drug therapy
    Adverse effects associated with the therapy
    Determination of adverse effects associated with the therapy
    Adverse effects associated with the therapy
    Determination of adverse effects associated with the therapy

    Secondary Outcome Measures

    Full Information

    First Posted
    November 29, 2021
    Last Updated
    January 18, 2022
    Sponsor
    Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
    Collaborators
    The Republican Center for Research and Practice in Otolaryngology
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05167552
    Brief Title
    Treatment of Allergic Rhinitis and Chronic Polypous Rhinosinusitis With Olfactory Mucosa-derived Mesenchymal Stem Cells
    Official Title
    Treatment of Patients With Allergic Rhinitis and Chronic Polypous Rhinosinusitis With Olfactory Mucosa-derived Mesenchymal Stem Cells
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    March 1, 2022 (Anticipated)
    Primary Completion Date
    December 31, 2023 (Anticipated)
    Study Completion Date
    December 31, 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
    Collaborators
    The Republican Center for Research and Practice in Otolaryngology

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Treatment of patients with allergic rhinitis and chronic polypous rhinosinusitis with olfactory mucosa-derived mesenchymal stem cells
    Detailed Description
    During the implementation of the project, the methods for the treatment of allergic rhinitis and chronic polypous rhinosinusitis with olfactory mucosa-derived mesenchymal stem cells will be developed. The positive outlook for the effectiveness of MSCs is due to the following: knowledge of the leading role of immunopathogenetic mechanisms in the development of allergic rhinitis and chronic polypous rhinosinusitis and the pronounced immunomodulating properties of MSCs; the ability of MSCs to reduce the production of proinflammatory cytokines and suppress immune inflammation; positive results of preclinical studies of the method of treatment of diseases accompanied by over-activation of the immune system, including autoimmune diseases, in animals and the first clinical studies in patients.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Allergic Rhinitis, Rhinosinusitis Chronic

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1, Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    60 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Patients with allergic rhinitis receiving standard treatment and mesenchymal stem cells
    Arm Type
    Experimental
    Arm Description
    Group 1: Patients with allergic rhinitis receiving standard treatment and olfactory mucosa-derived mesenchymal stem cells
    Arm Title
    Patients with chronic rhinosinusitis receiving standard treatment and mesenchymal stem cells
    Arm Type
    Experimental
    Arm Description
    Group 2: Patients with chronic polypous rhinosinusitis receiving standard treatment and olfactory mucosa-derived mesenchymal stem cells
    Arm Title
    Patients with allergic rhinitis receiving standard treatment
    Arm Type
    Active Comparator
    Arm Description
    Group 3: Patients with allergic rhinitis receiving standard treatment
    Arm Title
    Patients with chronic polypous rhinosinusitis receiving standard treatment
    Arm Type
    Active Comparator
    Arm Description
    Group 4: Patients with chronic polypous rhinosinusitis receiving standard treatment
    Intervention Type
    Biological
    Intervention Name(s)
    Olfactory mucosa-derived mesenchymal stem cells
    Intervention Description
    Olfactory mucosa-derived mesenchymal stem cells
    Intervention Type
    Other
    Intervention Name(s)
    Standard treatment of type Allergic Rhinitis according to the clinical protocols
    Intervention Description
    Standard treatment of type Allergic Rhinitis according to the clinical protocols
    Intervention Type
    Other
    Intervention Name(s)
    Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols
    Intervention Description
    Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols
    Primary Outcome Measure Information:
    Title
    The relapse-free period
    Description
    The duration of the relapse-free period
    Time Frame
    6 month
    Title
    The relapse-free period
    Description
    The duration of the relapse-free period
    Time Frame
    1 year
    Title
    The need for surgical intervention
    Description
    The need for surgical intervention
    Time Frame
    1 year
    Title
    The need for the use of basic drug therapy
    Description
    The need for the use of basic drug therapy
    Time Frame
    6 month
    Title
    The need for the use of basic drug therapy
    Description
    The need for the use of basic drug therapy
    Time Frame
    1 year
    Title
    Adverse effects associated with the therapy
    Description
    Determination of adverse effects associated with the therapy
    Time Frame
    1 month
    Title
    Adverse effects associated with the therapy
    Description
    Determination of adverse effects associated with the therapy
    Time Frame
    1 year

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Clinical diagnosis of allergic rhinitis or chronic polyposis rhinosinusitis The patient can read, understand, follow the examination procedures and complete, if necessary, the required documentation Written informed consent Exclusion Criteria: The presence of any malignant tumor within the last 5 years Acute or chronic diseases in the stage of decompensation Chronic infectious diseases: HIV, viral hepatitis B, C, tuberculosis Patients who are pregnant, breastfeeding, or fertile patients who are not using adequate contraceptive methods Chronic and protracted mental disorders, all diseases with the presence of the syndrome of dependence on alcohol, drugs and psychoactive substances, any other condition that makes the patient unable to understand the nature, extent and possible consequences of the study or, in the opinion of the researcher, prevents the patient from observing and performing protocol Patients are unable or unwilling to give written informed consent and / or follow research procedures Any other medical condition that, in the opinion of the investigator, may be associated with an increased risk to the patient or may affect the outcome or evaluation of the study
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Natalia Antonevich, Dr
    Phone
    +375173691763
    Email
    antonevich.n@gmail.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Andrei Hancharou, Dr
    Phone
    +375296248972
    Email
    hancharou@ibp.org.by
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Natalia Antonevich, Dr
    Organizational Affiliation
    the Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
    Official's Role
    Study Director
    First Name & Middle Initial & Last Name & Degree
    Yulia Eremenko, Prof
    Organizational Affiliation
    The Republican Center for Research and Practice in Otolaryngology
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Treatment of Allergic Rhinitis and Chronic Polypous Rhinosinusitis With Olfactory Mucosa-derived Mesenchymal Stem Cells

    We'll reach out to this number within 24 hrs